3-甲酰基-联苯-3-甲腈 | 400748-29-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-甲酰基-联苯-3-甲腈
• 中文别名: 3'-甲酰基-联苯-3-腈
• 英文名称: 3'-formyl-[1,1'-biphenyl]-3-carbonitrile
• 英文别名: 3-(3-Formylphenyl)benzonitrile
• CAS: 400748-29-0
• 化学式: C₁₄H₉NO
• 分子量: 207.232
• InChiKey: USIJZLBTVWMYBG-UHFFFAOYSA-N

物化性质

• 熔点：
  105-108°C
• 沸点：
  396.3±35.0 °C(Predicted)
• 密度：
  1.19±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  40.9
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2926909090

反应信息

• 作为反应物：
  描述：

  3-甲酰基-联苯-3-甲腈 在 吡啶 、 羟胺 、 乙酸酐 、 三乙酰氧基硼氢化钠 、 溶剂黄146 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Design, synthesis and structure–Activity relationships of benzoxazinone-Based factor Xa inhibitors

  摘要：

  A series of benzoxazinone derivatives was designed and synthesized as factor Xa inhibitors. We demonstrated that the naphthyl moiety in the aniline-based compounds I and 2 can be replaced with benzene-fused heterobicycles and biaryls to give factor Xa inhibitors with improved trypsin selectivity. The P4 modifications lead to monoamidines which are moderately active. The benzoxazinones 41-45 are potent against factor Xa, retain the improved trypsin selectivity of the corresponding aniline-based compounds, and show strong antithrombotic effect dose responsively. (C) 2002 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(02)00927-7
• 作为产物：
  描述：

  3-(3-cyanophenyl)-1-(bromomethyl)benzene 在 十二/十四烷基二甲基氧化胺 作用下， 以 氯仿 为溶剂， 生成 3-甲酰基-联苯-3-甲腈
  参考文献：
  名称：

  Design, synthesis and structure–Activity relationships of benzoxazinone-Based factor Xa inhibitors

  摘要：

  A series of benzoxazinone derivatives was designed and synthesized as factor Xa inhibitors. We demonstrated that the naphthyl moiety in the aniline-based compounds I and 2 can be replaced with benzene-fused heterobicycles and biaryls to give factor Xa inhibitors with improved trypsin selectivity. The P4 modifications lead to monoamidines which are moderately active. The benzoxazinones 41-45 are potent against factor Xa, retain the improved trypsin selectivity of the corresponding aniline-based compounds, and show strong antithrombotic effect dose responsively. (C) 2002 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(02)00927-7

文献信息

• [EN] 4,6-DIARYLAMINOTHIAZINES AS BACE1 INHIBITORS AND THEIR USE FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION<br/>[FR] 4,6-DIARYLAMINOTHIAZINES À TITRE D'INHIBITEURS DE BACE1 ET LEUR UTILISATION POUR RÉDUIRE LA PRODUCTION DES BÊTA-AMYLOÏDES
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2014098831A1

  公开（公告）日：2014-06-26

  Compounds of formula (I), including pharmaceutically acceptable salts thereof, are set forth herein: (I) wherein R1 and R2 are independently hydrogen, or -CH3; or R1 and R2 can join together in a ring by adding -(CH2)4-; R3 is hydrogen or C1-C3 alkyl; Y and Z are independently a C6-C10- aryl group or a 5-10 membered heterocyclic group which can be further substituted with from 0-3 substituents selected from the group of halogen, hydroxy, amino, C1-4alkylamino, C1-4 dialkylamino, haloC1-4 alkyl, CN, C1-C6 alkyl or cycloalkyl, C1-C6 alkoxy, -C=OC1-4 alkyl, -S02C1-4 alkyl, and C2-C4 alkynyl; A is selected from the group of phenyl, benzyl, oxazolyl, thiazolyl, isoxazolyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, and pyrazinyl groups which can be further substituted with from 0-3 substituents selected from the group of halogen, hydroxy, amino, C1-4alkylamino, C1-4 dialkylamino, haloC1-4 alkyl, hydroxyC1-6 alkyl, CN, C1-C6 alkyl or cycloalkyl, C1-C6 alkoxy, and C2-C4 alkynyl; L is -NHCO-, or is a single bond; and L and Z together can be absent.

  化合物的结构式（I），包括其药用盐，如下所示：（I），其中R1和R2分别是氢或-CH3；或者R1和R2可以通过添加-(CH2)4-在环中连接在一起；R3是氢或C1-C3烷基；Y和Z分别是C6-C10芳基或5-10成员杂环基，可以进一步用来自卤素、羟基、氨基、C1-4烷基氨基、C1-4二烷基氨基、卤代C1-4烷基、CN、C1-C6烷基或环烷基、C1-C6烷氧基、-C=OC1-4烷基、-S02C1-4烷基和C2-C4炔基的0-3取代基取代；A选自苯基、苄基、噁唑基、噻唑基、异噁唑基、咪唑基、吡唑基、吡啶基、嘧啶基和吡嗪基，可以进一步用来自卤素、羟基、氨基、C1-4烷基氨基、C1-4二烷基氨基、卤代C1-4烷基、羟基C1-6烷基、CN、C1-C6烷基或环烷基、C1-C6烷氧基和C2-C4炔基的0-3取代基取代；L为-NHCO-，或者是单键；而L和Z可以缺失。
• [EN] ANTIBACTERIAL BIAROMATIC DERIVATIVES<br/>[FR] DÉRIVÉS BI-AROMATIQUES ANTIBACTÉRIENS
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2014170821A1

  公开（公告）日：2014-10-23

  The invention relates to antibacterial compounds of formula I (I) wherein R is H, cyano, alkoxy, cyanomethoxy, cycloalkylmethoxy, hydroxyalkoxy, alkoxyalkoxy, alkoxycarbonyl, 2-ethoxy-2-oxoethoxy, 2-(methylamino)-2-oxoethoxy, (l-cyanocyclobutyl)methoxy, 3-hydroxy-pyrrolidin-l-yl or 3,4-dihydroxycyclopentyl)methoxy; U1 is N or CR1, U2 is N or CR2, U3 is N or CR3 and U4 is N or CR4, it being understood that at most three of U1, U2, U3 and U4 can be N at the same time; V1 is N or CR5, V2 is N or CR6, V3 is N or CR7 and V4 is N or CH, it being understood that at most two of V1, V2, V3 and V4 can be N at the same time; R1 is H, cyano, hydroxy or alkoxy; R2 is H, hydroxy or alkoxy; R3 is H, cyano, hydroxy, alkoxy or carboxamido; R4 is H or alkoxy; R5 is H, hydroxy or halogen; R6 is H, hydroxy or halogen; R7 is H; the dotted line "_____ " represents a bond or is absent; W represents CH or N when the dotted line "_____ " is a bond, or W represents CH2 when the dotted line "_____ " is absent; X represents CH or N; and Q represents O or S; and salts thereof.

  该发明涉及公式I（I）的抗菌化合物，其中R是H、氰基、烷氧基、氰甲氧基、环烷基甲氧基、羟基烷氧基、烷氧基烷氧基、烷氧基羰基、2-乙氧基-2-氧基乙氧基、2-(甲基氨基)-2-氧基乙氧基、(1-氰基环丁基)甲氧基、3-羟基吡咯烷-1-基或3,4-二羟基环戊基)甲氧基；U1是N或CR1，U2是N或CR2，U3是N或CR3，U4是N或CR4，理解为U1、U2、U3和U4中最多有三个可以同时为N；V1是N或CR5，V2是N或CR6，V3是N或CR7，V4是N或CH，理解为V1、V2、V3和V4中最多有两个可以同时为N；R1是H、氰基、羟基或烷氧基；R2是H、羟基或烷氧基；R3是H、氰基、羟基、烷氧基或羧胺基；R4是H或烷氧基；R5是H、羟基或卤素；R6是H、羟基或卤素；R7是H；虚线"_____"代表键或不存在；W代表CH或N，当虚线"_____"为键时，或W代表CH2，当虚线"_____"不存在时；X代表CH或N；Q代表O或S；及其盐。
• 4,6-DIARYLAMINOTHIAZINES AS BACE1 INHIBITORS AND THEIR USE FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20150329506A1

  公开（公告）日：2015-11-19

  Compounds of formula (I), including pharmaceutically acceptable salts thereof, are set forth herein: (I) wherein R 1 and R 2 are independently hydrogen, or —CH 3 ; or R 1 and R 2 can join together in a ring by adding —(CH 2 ) 4 —; R 3 is hydrogen or C 1 -C 3 alkyl; Y and Z are independently a C 6 -C 10 -aryl group or a 5-10 membered heterocyclic group which can be further substituted with from 0-3 substituents selected from the group of halogen, hydroxy, amino, C 1-4 alkylamino, C 1-4 dialkylamino, haloC 1-4 alkyl, CN, C 1 -C 6 alkyl or cycloalkyl, C 1 -C 6 alkoxy, —C═OC 1-4 alkyl, —SO 2 C 1-4 alkyl, and C 2 -C 4 alkynyl; A is selected from the group of phenyl, benzyl, oxazolyl, thiazolyl, isoxazolyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, and pyrazinyl groups which can be further substituted with from 0-3 substituents selected from the group of halogen, hydroxy, amino, C 1-4 alkylamino, C 1-4 dialkylamino, haloC 1-4 alkyl, hydroxyC 1-6 alkyl, CN, C 1 -C 6 alkyl or cycloalkyl, C 1 -C 6 alkoxy, and C 2 -C 4 alkynyl; L is —NHCO—, or is a single bond; and L and Z together can be absent.

  本文列出了公式（I）的化合物，包括其中的药物可接受的盐：（I）其中R1和R2分别为氢或-CH3；或R1和R2可以通过添加-(CH2)4-形成环；R3为氢或C1-C3烷基；Y和Z分别为C6-C10芳基或5-10成员的杂环基，可以进一步用来自卤素、羟基、氨基、C1-4烷基氨基、C1-4双烷基氨基、卤C1-4烷基、CN、C1-C6烷基或环烷基、C1-C6烷氧基、-C═OC1-4烷基、-SO2C1-4烷基和C2-C4炔基的0-3个取代基进行取代；A选自苯基、苄基、噁唑基、噻唑基、异噁唑基、咪唑基、吡唑基、吡啶基、嘧啶基和吡嗪基，可以进一步用来自卤素、羟基、氨基、C1-4烷基氨基、C1-4双烷基氨基、卤C1-4烷基、羟基C1-6烷基、CN、C1-C6烷基或环烷基、C1-C6烷氧基和C2-C4炔基的0-3个取代基进行取代；L为-NHCO-或单键；L和Z可以一起不存在。
• Antibacterial Biaromatic Derivatives
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：US20160075722A1

  公开（公告）日：2016-03-17

  The invention relates to antibacterial compounds of formula I (I) wherein R is H, cyano, alkoxy, cyanomethoxy, cycloalkylmethoxy, hydroxyalkoxy, alkoxyalkoxy, alkoxycarbonyl, 2-ethoxy-2-oxoethoxy, 2-(methylamino)-2-oxoethoxy, (1-cyanocyclobutyl)methoxy, 3-hydroxy-pyrrolidin-1-yl or 3,4-dihydroxycyclopentyl)methoxy; U 1 is N or CR 1 , U 2 is N or CR 1 , U 3 is N or CR 3 and U 4 is N or CR 1 , it being understood that at most three of U 1 , U 2 , U 3 and U 4 can be N at the same time; V 1 is N or CR 5 , V 2 is N or CR 6 , V 3 is N or CR 7 and V 4 is N or CH, it being understood that at most two of V 1 , V 2 , V 3 and V4 can be N at the same time; R1 is H, cyano, hydroxy or alkoxy; R2 is H, hydroxy or alkoxy; R 3 is H, cyano, hydroxy, alkoxy or carboxamido; R 4 is H or alkoxy; R 5 is H, hydroxy or halogen; R 6 is H, hydroxy or halogen; R 7 is H; the dotted line “______” represents a bond or is absent; W represents CH or N when the dotted line “______” is a bond, or W represents CH 2 when the dotted line “______” is absent; X represents CH or N; and Q represents O or S; and salts thereof.

  本发明涉及式I的抗菌化合物（I），其中R为H，氰基，烷氧基，氰甲氧基，环烷基甲氧基，羟基烷氧基，烷氧基烷氧基，烷氧基羧酰基，2-乙氧基-2-氧代乙氧基，2-（甲基氨基）-2-氧代乙氧基，（1-氰基环丁基）甲氧基，3-羟基吡咯烷-1-基或3,4-二羟基环戊基）甲氧基；U1为N或CR1，U2为N或CR1，U3为N或CR3，U4为N或CR1，其中最多只能同时有三个U1，U2，U3和U4为N；V1为N或CR5，V2为N或CR6，V3为N或CR7，V4为N或CH，其中最多只能同时有两个V1，V2，V3和V4为N；R1为H，氰基，羟基或烷氧基；R2为H，羟基或烷氧基；R3为H，氰基，羟基，烷氧基或羧酰胺基；R4为H或烷氧基；R5为H，羟基或卤素；R6为H，羟基或卤素；R7为H；虚线“______”表示键或不存在；当虚线“______”为键时，W表示CH或N，当虚线“______”不存在时，W表示CH2；X表示CH或N；Q表示O或S；以及其盐。
• Enhancing nicotinamide N-methyltransferase bisubstrate inhibitor activity through 7-deazaadenosine and linker modifications
  作者：Pengyu Li、Cuicui Xia、Xiangqian Kong、Jiancun Zhang

  DOI：10.1016/j.bioorg.2023.106963

  日期：2024.2

  [Display omitted]

   [显示省略]